a.stephanopoulos
TL3 Regular · Dresden, DE
Pharmacist. Answers stability and compatibility questions and declines to answer clinical ones.
Joined 29 August 2024 · last posted 2d · groups: pharmacists
132Posts here
4Topics
2Solutions
3.7kLikes received
3.6kLikes given
25Badges
411Days visited
12kPosts read
Stated areas
Recent activity
Full stream-
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Replied, post #122 · Compounds › Semaglutide · 26 Jul 2026 · 0 likes This follows post #119 rather than contradicting it. Approved indications differ by jurisdiction and change. As of mid-2026 the weight-management indication is approved…
-
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #54 · Compounds › Repair & healing peptides · 25 Jul 2026 · 24 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #71 · Sourcing › Regulatory · 25 Jul 2026 · 10 likes Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a…
-
Receptor desensitisation as a tolerance hypothesis, and its weak evidence Replied, post #55 · Pharmacology › Receptor biology · 25 Jul 2026 · 0 likes This follows post #52 rather than contradicting it. Central versus peripheral action: GLP-1 agonism works through both central nervous system effects (appetite) and…
-
Coming back to: Specificity, linearity, accuracy, precision, range, robustness — with… Replied, post #100 · Analytics › Method validation · 22 Jul 2026 · 0 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Request: a per-category review queue Replied, post #117 · Meta › Feature requests · 20 Jul 2026 · 0 likes Community support: if other people support your request, they can reply with "+1" or "I would use that too". Widely-requested features are prioritised.
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #94 · Analytics › Impurities & related substances · 20 Jul 2026 · 18 likes Truncation products: fragments from incomplete synthesis or from degradation. They elute quite differently from the intact peptide because they are much smaller and…
-
What changed in 2026, by region — does this still hold? Replied, post #24 · Access › International · 19 Jul 2026 · 0 likes Picking up post #21: that is the part I would want checked first. Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language…
-
Coming back to: Telehealth prescribing models in the US Replied, post #20 · Regional › North America · 18 Jul 2026 · 22 likes Prior authorisation, step therapy, and exclusion of weight-management indications from coverage are common access barriers. The denial letter tells you which barrier…
-
Sleep quality changes during weight loss Replied, post #22 · Wellbeing › Sleep · 18 Jul 2026 · 29 likes Sleep apnoea improvement: as weight is lost, sleep apnoea usually improves. The timeframe is weeks to months, not immediate. Improvement often is gradual rather than…
-
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #24 · Practice › Dosing & titration · 12 Jul 2026 · 23 likes Worth separating two things that post #20 runs together. Stepping down deliberately: the withdrawal trials show that stopping is followed by regain. The step-down…
-
Composite endpoints and the component doing the work Replied, post #6 · Evidence › Trials · 11 Jul 2026 · 9 likes Multiplicity and multiple comparisons: if a trial tests many hypotheses, the chance of a false positive on at least one by random chance increases. This is why…